Details about Mary K. Olson

Access statistics for papers by Mary K. Olson.

Last updated 2022-12-30. Update your information in the RePEc Author Service.

Short-id: pol152

Working Papers

1992

1. Pharmaceutical Expenditure and Regulatory Policy in the NHS
   Working Papers, Washington St. Louis - School of Business and Political Economy

Journal Articles

2021

1. New clinical information and physician prescribing: How do pediatric labeling changes affect prescribing to children?
   Health Economics, 2021, 30, (1), 144-164 View citations (1)

2018

2. Examining Firm Responses to R&D Policy: An Analysis of Pediatric Exclusivity
   American Journal of Health Economics, 2018, 4, (3), 321-357 View citations (8)
   Also in American Journal of Health Economics, 2018, 4, (3), 321-357 (2018) View citations (8)

2013

3. Eliminating the U.S. drug lag: Implications for drug safety
   Journal of Risk and Uncertainty, 2013, 47, (1), 1-30 View citations (2)

2008

4. The risk we bear: The effects of review speed and industry user fees on new drug safety
   Journal of Health Economics, 2008, 27, (2), 175-200 View citations (16)

2004

5. Are novel drugs more risky for patients than less novel drugs?
   Journal of Health Economics, 2004, 23, (6), 1135-1158 View citations (19)

2002

6. Pharmaceutical Policy Change and the Safety of New Drugs
   Journal of Law and Economics, 2002, 45, (S2), 615-642 View citations (16)

2000

7. Regulatory Reform and Bureaucratic Responsiveness to Firms: the Impact of User Fees in the FDA
   Journal of Economics & Management Strategy, 2000, 9, (3), 363-395 View citations (3)

1999

8. Agency Rulemaking, Political Influences, Regulation, and Industry Compliance
   The Journal of Law, Economics, and Organization, 1999, 15, (3), 573-601 View citations (7)

1997

9. Firm Characteristics and the Speed of FDA Approval
   Journal of Economics & Management Strategy, 1997, 6, (1), 377-401 View citations (18)

1996

10. Substitution in Regulatory Agencies: FDA Enforcement Alternatives
    The Journal of Law, Economics, and Organization, 1996, 12, (2), 376-407 View citations (13)

1995

11. Regulatory Agency Discretion among Competing Industries: Inside the FDA
    The Journal of Law, Economics, and Organization, 1995, 11, (2), 379-405 View citations (17)
12. The Effects of UK Pharmaceutical Policy on Government Drug Expenditure: Cost Control and Incentives for R&D
    International Journal of the Economics of Business, 1995, 2, (1), 51-64 View citations (1)

1994

13. Political Influence and Regulatory Policy: The 1984 Drug Legislation
    Economic Inquiry, 1994, 32, (3), 363-82 View citations (1)